tetano
Editor, Senior Moderator
Intern Med
. 2021 Dec 4.
doi: 10.2169/internalmedicine.7971-21. Online ahead of print.
Tacrolimus Treatment for Post-COVID-19 Interstitial Lung Disease
Migiwa Ohgushi[SUP] 1 [/SUP], Naruhiko Ogo[SUP] 2 [/SUP], Toyoshi Yanagihara[SUP] 2 [/SUP], Yukiko Harada[SUP] 1 [/SUP], Kosuke Sumida[SUP] 1 [/SUP], Ayaka Egashira[SUP] 1 [/SUP], Tatsuma Asoh[SUP] 1 [/SUP], Takashige Maeyama[SUP] 2 [/SUP], Seiji Yoshizawa[SUP] 1 [/SUP]
Affiliations
Abstract
With expansion of the COVID-19 pandemic, reports of post-COVID-19 interstitial lung disease (ILD) have been emerging. However, there are few reports regarding treatment. Some reports indicate that corticosteroids are effective for post-COVID-19 ILD, but the use of long-term corticosteroid carries risks of side effects. We administered tacrolimus to an elderly patient with post-COVID-19 ILD who suffered a respiratory failure relapse during steroid tapering. The respiratory status improved with tacrolimus in the post-acute phase, but pulmonary fibrosis progressed in the late phase. Tacrolimus may be effective for treating post-COVID-19 ILD in the post-acute phase, but it does not halt progression of pulmonary fibrosis.
Keywords: COVID19; Coronavirus disease 2019; immunosuppressive agent; interstitial lung disease; respiratory failure; tacrolimus.
. 2021 Dec 4.
doi: 10.2169/internalmedicine.7971-21. Online ahead of print.
Tacrolimus Treatment for Post-COVID-19 Interstitial Lung Disease
Migiwa Ohgushi[SUP] 1 [/SUP], Naruhiko Ogo[SUP] 2 [/SUP], Toyoshi Yanagihara[SUP] 2 [/SUP], Yukiko Harada[SUP] 1 [/SUP], Kosuke Sumida[SUP] 1 [/SUP], Ayaka Egashira[SUP] 1 [/SUP], Tatsuma Asoh[SUP] 1 [/SUP], Takashige Maeyama[SUP] 2 [/SUP], Seiji Yoshizawa[SUP] 1 [/SUP]
Affiliations
- PMID: 34866097
- DOI: 10.2169/internalmedicine.7971-21
Abstract
With expansion of the COVID-19 pandemic, reports of post-COVID-19 interstitial lung disease (ILD) have been emerging. However, there are few reports regarding treatment. Some reports indicate that corticosteroids are effective for post-COVID-19 ILD, but the use of long-term corticosteroid carries risks of side effects. We administered tacrolimus to an elderly patient with post-COVID-19 ILD who suffered a respiratory failure relapse during steroid tapering. The respiratory status improved with tacrolimus in the post-acute phase, but pulmonary fibrosis progressed in the late phase. Tacrolimus may be effective for treating post-COVID-19 ILD in the post-acute phase, but it does not halt progression of pulmonary fibrosis.
Keywords: COVID19; Coronavirus disease 2019; immunosuppressive agent; interstitial lung disease; respiratory failure; tacrolimus.